Daihan Scientific
Key metrics
Earnings
| Revenue, Q3 2026 | ₩21.5bn |
|---|---|
| Revenue QoQ | -0.8% |
| Revenue YoY | +1.2% |
| Operating income, Q3 2026 | ₩2.3bn |
| Operating income QoQ | +12.5% |
| Operating income YoY | +0.6% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩5.1bn |
|---|---|
| Supply contracts vs prior-year revenue | 6.3% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 3 |
|---|---|
| DART filings, previous 3 months | 6 |
Insider transactions
| Open-market buys, last 12 months (shares) | 124,642 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩487m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 124,642 shares |
| Insiders who bought, last 12 months | 2 |
Insider transactions (last 12 months)
Open-market buys: 124,642 shares (₩487m). Open-market sells: 0 shares (₩0). Net open-market buying: +124,642 shares. Insiders who bought: 2.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | Seo Hyeon-jeong (Registered director) | Open-market buy | +10 shares | ₩3,597 | ₩35,970 | |
| Oct 29, 2026 | Lee Chung-hyeong (Registered director) | Open-market buy | +14,008 shares | ₩3,743 | ₩52m | |
| Oct 28, 2026 | Seo Hyeon-jeong (Registered director) | Open-market buy | +27,757 shares | ₩3,457 | ₩96m | |
| Oct 28, 2026 | Lee Chung-hyeong (Registered director) | Open-market buy | +13,045 shares | ₩3,643 | ₩48m | |
| Jun 29, 2026 | Seo Hyeon-jeong (Registered director) | Open-market buy | +921 shares | ₩3,597 | ₩3m | |
| Jun 29, 2026 | Lee Chung-hyeong (Registered director) | Open-market buy | +20,139 shares | ₩3,691 | ₩74m | |
| Jun 26, 2026 | Seo Hyeon-jeong (Registered director) | Open-market buy | +7,707 shares | ₩3,457 | ₩27m | |
| Jun 26, 2026 | Lee Chung-hyeong (Registered director) | Open-market buy | +7,329 shares | ₩3,484 | ₩26m | |
| Apr 17, 2026 | Seo Hyeon-jeong (Registered director) | Open-market buy | +6,716 shares | ₩4,691 | ₩32m | |
| Feb 19, 2026 | Lee Chung-hyeong (Registered director) | Open-market buy | +20,678 shares | ₩4,829 | ₩100m | |
| Jan 26, 2026 | Lee Chung-hyeong (Registered director) | Open-market buy | +6,332 shares | ₩4,731 | ₩30m |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩81.1bn | ₩5.5bn |
| 2024 | ₩71.7bn | ₩4.2bn |
| 2023 | ₩73.7bn | ₩6.2bn |
Filing timeline
-
Supply contract for QC analytical equipment worth ₩5.1bn
Daihan Scientific filed a supply contract for QC analytical equipment with PT Daewoong Pharmaceutical Indonesia, worth ₩5.1bn and reported as 6.3% of revenue. The contract period runs from Oct 7, 2026 to Jan 31, 2027.